Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Compliant postmenopausal women with primary operable breast cancer after complete surgery and suitable for endocrine treatment
Nodal status negative or positive
Good Health status 0-2 (Eastern Cooperative Oncology Group)
Estrogen- and/or progesterone-receptor positive
Adequate marrow, kidney and liver function
You may not be if
Metastatic or inflammatory breast cancer
Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancer or in situ cancer of the cervix. Patients with other previous cancers must have been disease-free for at least 5 years and Patients with uncontrolled, non-malignant systemic cardiovascular, kidney, and liver diseases.
Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures.
Recent (within 6 weeks) or planned dental or jaw surgery
Patients with primary overactive parathyroid
Patients with a known hypersensitivity to zoledronic acid or other bisphosphonates.
Clareo Health | Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
